Bluebird bio has its first approval for Skysona (formerly Lenti-D), its gene therapy for children with the rare disease cerebral adrenoleukodystrophy (CALD), after getting the nod from the EU ...

The FDA said it is evaluating the need for additional regulatory action regarding the safety of bluebird bio’s (NASDAQ:BLUE) gene therapy Skysona, which is used to treat children with cerebral ...

The gene therapy – Skysona (elivaldogene autotemcel) was approved by the US regulator in 2022, becoming the therapy shown to slow the progression of neurologic dysfunction in boys with the ...

LONDON, GREATER LONDON, UNITED KINGDOM, February 5, 2025 /EINPresswire / -- What's Driving the Skysona Market in Recent Years? According to the Skysona Global Market Report 2025 , the market size ...